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Abstract
Background: We report a 6.5 year-old female with a homozygous missense mutation in ZFYVE20, encoding
Rabenosyn-5 (Rbsn-5), a highly conserved multi-domain protein implicated in receptor-mediated endocytosis.
The clinical presentation includes intractable seizures, developmental delay, microcephaly, dysostosis, osteopenia,
craniofacial dysmorphism, macrocytosis and megaloblastoid erythropoiesis. Biochemical findings include transient
cobalamin deficiency, severe hypertriglyceridemia upon ketogenic diet, microalbuminuria and partial cathepsin D
deficiency.
Methods and results: Whole exome sequencing followed by Sanger sequencing confirmed a rare
(frequency:0.003987) homozygous missense mutation, g.15,116,371 G > A (c.1273G > A), in ZFYVE20 resulting in an
amino acid change from Glycine to Arginine at position 425 of the Rbsn protein (p.Gly425Arg), as the only
mutation segregating with disease in the family. Studies in fibroblasts revealed expression and localization of
Rbsn-5G425R in wild-type manner, but a 50% decrease in transferrin accumulation, which is corrected by wild-type
allele transfection. Furthermore, the patient’s fibroblasts displayed an impaired proliferation rate, cytoskeletal and
lysosomal abnormalities.
Conclusion: These results are consistent with a functional defect in the early endocytic pathway resulting from
mutation in Rbsn-5, which secondarily disrupts multiple cellular functions dependent on endocytosis, leading to a
severe multi-organ disorder.
Keywords: Internalization, Receptor endocytosis, Recycling, FYVE domain, Rab GTPase, Epilepsy, Cathepsin D,
Vitamin B12, Inborn error of metabolism
Introduction
As of 2014, an estimated 1,800 Mendelian conditions
remain to be identified (http://www.omim.org/statistics/
entry). We recently have established a research program
(www.tidebc.org) using whole exome sequencing (WES)
in patients with unexplained metabolic phenotypes to
diagnose/discover inborn errors of metabolism as a potential
cause of their intellectual disability and/or developmental
delay [1]. Here we report such a case, in which a mutation
in the gene ZFYVE20, encoding the protein Rabenosyn-5
(Rbsn-5), is the likely cause of a complex condition in a fe-
male child characterized by developmental delay, intract-
able epileptic encephalopathy, and a pleiotropic clinical
and biochemical phenotype.
Rbsn-5 is a large, evolutionarily conserved multidomain
protein expressed ubiquitously in mammalian cells and
implicated in receptor-mediated endocytosis [2-5]. The
specific role of Rbsn-5 is to regulate the intracellular route
of internalized receptors, facilitating their recycling to the
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plasma membrane [5-7]. By controlling the rate of recyc-
ling of numerous receptors, Rbsn-5 affects critical cellular
functions, amongst which are the absorption and cellular
uptake of high molecular weight nutrients, the signaling
capacity of growth factor and neurotransmitter receptors,
and the ability of integrins to control cellular motility. At
the molecular level, Rbsn-5 controls receptor recycling
[5,7] through direct interactions with regulatory proteins
and lipids, which include the endocytic GTPases Rab4 and
Rab5, and phosphatidylinositol-3 phosphate, the product
of the class III PI-3 kinase Vps34 [6,8-10]. Thus, muta-
tions that cause structural alterations in specific regions of
Rbsn-5 are likely to disrupt the balance of interactions
with one or more of these regulatory factors, and lead to
widespread abnormalities in receptor recycling dynamics.
Transferrin (Tf ) is frequently used to monitor endo-
cytosis and recycling, due to the abundance of transfer-
rin receptors in primary and cultured cells, as well as
the property of Tf to become internalized and quantita-
tively recycled. Rbsn-5 depletion in cultured mamma-
lian cells impairs Tf trafficking [5-7] by interfering with
recycling, and can lead to decreased receptor levels [5].
High-resolution live cell imaging studies have shown
that Rbsn-5 is localized to endosomes to which Tf is de-
livered immediately following its internalization from
clathrin-coated pits at the plasma membrane [5].
We have used this approach to determine how the mu-
tation in Rbsn-5 in this patient impairs endocytosis and
recycling. Additional biochemical and morphological ap-
proaches have been used to further understand the pleio-
tropic cellular consequences of this disruption. Possible
mechanisms by which these defects culminate in the over-
all clinical presentation in this patient are discussed.
Methods
This study was initiated as part of the Treatable Intellec-
tual Disability Endeavor in British Columbia and approved
by the institutional review boards of BC Children’s Hos-
pital and the University of British Columbia (CW12-0019/
H12-00067). Parents provided written informed consent.
Whole exome sequencing
Index and unaffected parental sequencing was conducted
using Agilent SureSelect kit and Illumina HiSeq 2000
(Perkin-Elmer, Santa Clara, California, USA) (REB Ap-
proval CW12-0019 / H12-00067) Approximately 50.2
million 100 bp pair-end reads were generated per par-
ticipant. A combination of Bowtie, BWA and GSNAP
was used to map the reads to hg19 reference genome,
and Samtools was used to call the variations relative to
the reference. On average, 99% of the observed variations
were classified as common variants based on a reported
allele frequency in dbSNP (version 135). The remaining
set of rare or novel variants (defined as <0.01 minor allele
frequency) was assessed for potential to disrupt protein
function using the Sift and PolyPhen2 software systems,
and was also screened under a series of genetic models
with a focus on Mendelian recessive modes of inheritance.
PCR
Exome sequencing results of the mutations in ZFYVE20
were validated in the index and unaffected parents (with
targeted mutation analysis in the unaffected siblings),
Sanger DNA sequencing using standard PCR conditions
with an annealing temp of 59°C. (primer 1: GGGTCTG
AGTCCTCACTCTGC, primer 2: TGTCACTGGCACAG
GGATAG).
Cell culture and transfection
CB and PA cells were maintained in MEM 2% FBS. Cells
were transfected using electroporation, plated on glass
coverslips (Thomas Scientific 25 circle #1.5), and grown
for 48 hours. Live imaging was done in KRH buffer
(125 M NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4,
25 mM HEPES, 2.5% BSA and 2 mM sodium pyruvate)
pH 7.4.
TIRF/Epi-fluorescence structure-illumination microscope
(TESM) optical system
A custom-built microscope system, TESM, simultaneously
combines Total Internal Reflection Fluorescence and
wide-field epifluorescence modes and incorporates struc-
tured illumination in the epi mode for fast optical section-
ing and enhanced spatial resolution. Further details as
well as the TESM acquisition system is described previ-
ously [5]. For quantification, image sets were convolved
with a difference of Gaussians (DOG) filter consisting of
1) a small, two dimensional, Gaussian spot with unit area
(sigma = 150 nm) that acted as a vesicle matched detector,
i.e. an approximation to a near-diffraction limited spot,
and 2) a larger, inverted, two dimensional Gaussian
(sigma = 300 nm) with negative unit area that estimated
and subtracted the local background. The Gaussian
smoothed images were visually thresholded (global
threshold) to select for pixels belonging to objects (e.g. vesi-
cles) and eliminate areas devoid of signal (but containing
noise). The total intensity per cell over time was recorded.
Reagents
The TagRFP-T expression vector was constructed as
described [11]. The cDNA clone 40034008 for human
Rabenosyn-5 was obtained from American Tissue Cul-
ture Collection (Manassas, VA) and was cloned in frame
with TagRFP-T at the N terminus of the protein using
standard techniques. Polyclonal EEA1 and Rbsn-5 anti-
bodies have been described [5]. Unconjugated and
DyLight-conjugated human transferrin were obtained
from Jackson Immunochemicals.
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Electron microscopy
Fibroblasts were fixed and postfixed in phosphate buff-
ered 2.5% glutaraldehyde and osmium tetroxide respect-
ively, dehydrated in an ascending series of acetone and
infiltrated and embedded in epon araldite, and ultrathin
sections were prepared and mounted on grids prior to
examination in the electron microscope.
Cathepsin D analysis
Goat anti-human CatD antibody was used to visualize
the 53-kDa proenzyme precursor (preCatD) and the proc-
essed 33 kDa heavy chain (CatD) of cathepsin D by western
blotting. Blots were stained with Lumi Light Western blot-
ting substrate (Roche Diagnostics, Mannheim, Germany)
to visualize the 53-kDa proenzyme precursor (preCatD)
and the processed 33 kDa heavy chain (CatD) of cathepsin
D by chemiluminescence [12].
Results
History and physical exam
This 6.5 year-old girl was born as the second of 3 sisters
to healthy non-consanguineous Caucasian parents after
an uneventful pregnancy. She developed pharmaco-
resistant infantile spasms at age 5 months, which improved
upon ketogenic diet (KD) started at age 14 months. Severe
hypertriglyceridemia (plasma triglycerides: 90 mmol/L,
normal 0.36-1.31) observed at age 50 months was revers-
ible by reduction of natural fat in the KD, and partial
replacement with medium chain triglycerides. Her cranial
1.5 T MRI, at age 40 months showed moderate enlarge-
ment of the 3rd ventricle, normal myelination and cortical
architecture.
At 6.5 y she is clinically seizure free upon the modified
KD and four anticonvulsive drugs (Valproic acid, Pheno-
barbital, Levetiracetam, Lamotrigine). Her biparietal head
circumference is 46 cm (below the 0.1st percentile); weight
and height at the 3rd and 0.1st percentile. She is hypotonic,
able to sit without support, but unable to stand or walk.
She has a happy, friendly demeanor, is non-verbal and
unable to feed herself and not toilet-trained. She has thin,
whispy hair and dysmorphic facial features (Figure 1A).
A skeletal survey at chronological age 6 years revealed
a moderate osteopenia involving the pelvis and long
bones of both upper and lower limbs with evidence of
undertubulation and hypoplasia of the epiphyses around
the knee joint and bilateral coxa valga. Particularly the
long bones of the right hand appear undertubulated and
osteopenic. (Figure 1B) with delayed appearance of the
right carpal bones (approximate bone age 2.5 years).
Clinical biochemistry
At 14 months of age (prior to start of the ketogenic
diet), biochemical genetic assessment revealed repeatedly
normal results for blood lactate and ammonia levels,
plasma and CSF aminoacids, plasma very long chain fatty
acids, pipecolic acid, and transferrin phenotyping, urine
excretion of purines and pyrimidines, creatine, guani-
dinoacetate, glycosaminoglycans, oligosaccharides and
α-aminoadipic acid semialdehyde. Urinary organic acid
analysis revealed high urine methylmalonic acid con-
centration (40 mmol/mol creatinine, normal < 5.13) along
with mildly elevated plasma homocysteine (13.7 μmol/L,
normal <7) and low cobalamin (vitamin B12) levels (66
and 60 pmol/L, deficient range < 107). The child was
breastfed until age 14 months when she started the ke-
togenic diet. The mother had been on a normal, vitamin
Figure 1 Clinical features of a girl with a point mutation in
Rabenosyn-5. A: Facial features showing midfacial bone hypoplasia,
deep set eyes with a hooded appearance, a fullness in the nasal
bridge, a short nose and a large mouth with small teeth and tongue
protrusion. B: PA view of right hand showing marked under
mineralization, coned epiphyses, under tubulated long bones, and
relatively short digits particularly involving the middle phalanges of
digit 2 and digit 5. Delayed skeletal maturation at approximately
2 years 6 months for a chronological age of 6 years 2 months and a
single standard deviation of 10 months. C-F: Bone marrow aspirates
showing megaloblastoid erythropoiesis (C and D), occasional
intercytoplasmic bridging (C), mild increase in reticulin fibrosis
throughout most of the bone marrow (E). Foamy macrophages
most notably in the bone marrow biopsy specimen (F).
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B12 containing diet throughout pregnancy and the time
of breastfeeding. At the time vitamin B12 deficiency was
diagnosed in her child, her plasma vitamin B12 levels
were within non-deficient range (178 pmol/L, normal
156–698), her plasma homocysteine level was 13 μmol/L
(normal 6–12.8), her CBC, urine organic acid profile and
blood acylcarnitine profile were normal. Cobalamin levels
in the child increased significantly (up to 1107 pmol/L)
after intramuscular injection of vitamin B12 (cyanocobala-
min 1000 μg) on 10 subsequent days, and remained within
non-deficient range (471 pmol/L, non deficient range:
133–675) upon continuous oral supplementation of cyano-
cobalamin (250 μg per day) when measured at 26 months
of age. Homocysteine remained normal when measured at
various occasions (3.1, 5.0, 2.5 μmol/L), but urine and
serum MMA levels remained mildly elevated when mea-
sured at 29 and 40 months of age (urine: 31 and 32 mmol/
mol creatinine, normal < 5.13; serum: 0.21 at 40 months,
normal 0.018-0.150).
Defects of cobalamin absorption, transport and intra-
cellular metabolism were excluded by respective tests in
blood and cultured fibroblasts (Table 1). Also detected
were microalbuminuria (microalbumin/creatinine ratio =
15.6 - 26.8, normal <2.7) and high urinary Ca excretion
(calcium/creatine ratio = 3.73, normal <1.1) in the presence
of normal plasma 25 OH Vitamin D, calcium, phosphorus
and alkaline phosphatase levels.
Clinical hematologic findings
Red blood cell macrocytosis (range: 95.5-104.6 fl; mean:
98.8; n = 21; normal 75–87) was noted prior to initiation
of the ketogenic diet and persisted throughout the entire
observation period. Transient neutropenia occurred be-
tween age 40 and 44 months (range: 0.7-1.3 × 109/L,
mean: 0.9, n = 4; normal: 1.5-8.5). A bone marrow aspirate
and biopsy at age 44 months showed normocellularity for
age with a normal myeloid to erythroid ratio (2:1) (Figure 1
C-F). A mild increase in reticulin fibrosis (2+ out of 4) but
no collagen deposition were present. No significant dys-
plastic features were seen in the granulocytic and mega-
karyocytic lineages. Foamy macrophages were attributed
to the marked hyperlipidemia present at the time of bone
marrow sampling. Peripheral blood morphology at the
time of bone marrow biopsy showed increased target
cells and stomatocytes. Erythropoiesis showed megalo-
blastoid change with some erythroblasts showing fea-
tures approaching a true megalosblastic state, however
no neutrophil hypersegmentation nor giant myelocytes
or metamyelocytes were present and iron stains did not
show ring sideroblasts. Cytogenetic studies were unre-
markable at the time. Plasma copper, zinc and folate,
erythrocyte folate, serum iron and ferritin and transfer-
rin saturation were normal on repeated occasions.
Genetic analyses
The patients karyotype and chromosomal microarray
analysis (AffymetrixCytoscan® HD) were unremarkable;
homozygosity analysis did not reveal evidence of consan-
guinity or uniparental disomy. WES was performed for
the index and her unaffected parents. Rare variants were
assessed for their potential to disrupt protein function and
screened under a series of genetic models—primarily the
Table 1 Studies of cobalamin absorption, transport, cellular uptake and intracellular metabolism in a patient with a
homozygous G425R mutation in ZFYVE20
Intrinsic Factor antibodies Negative antibodies
Parietal Cell antibodies
Gastric Intrinsic Factor Protein (GIF) No pathogenic mutations on WES (coverage × 30, last 5 exons of AMN × 3–5)
Cubilin (CUB)
Megalin (LRP2)
Amnioless (AMN)
Total Haptocorrin (TCN1) 592 pmol/L (normal 240–680)
Plasma Total Transcobalamin (TCNII)* 1520 pmol/L (normal 500–1.500)
Plasma Holotranscobalamin* 182 pmol/L (normal 40–160)
Transcobalamin Receptor related genes (TCbR, CD320, TCN1, TCN2) Absence of (262_264delGAG and 297delA) by targeted mutation analysis [17]
No pathogenic mutations by WES (coverage > × 20)
[14C]-propionate incorporation (f) 11.0 nmol/mg protein/18 h (normal 10.8 ± 3.7 nmol/mg protein/18 h)
[14C]-methylene tetrahydrofolate incorporation (f) 250 pmol/mg protein/18 h (normal 225 ± 165 pmol/mg protein/18 h)
[57Co]-cyanocobalamin uptake (f) 16.9 pg/106 cells (normal 13.2 ± 4.8 pg/106)
[57Co]-cyanocobalamin conversion to adenosylcobalamin (f) 5.7. % of intracellular cobalamin (normal 15.3 ± 4.2)
[57Co]-cyanocobalamin coversion to methylcobalamin (f) 53.0% (normal 58.0 ± 6.7)
(f) = fibroblasts; *by courtesy Ebba Nexo, Arhus, DK.
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Mendelian recessive mode of inheritance given the rarity
of the phenotype and the pattern of inheritance of most
IEMs.
Approximately 99% of the observed variations were
classified as common (results not shown). Two rare (de-
fined as <0.01 minor allele frequency) candidate variants
fit the compound heterozygous model autosomal recessive
model of homozygous WES revealed a total of 5 genes
harboring compound heterozygous variants and 3 genes
with homozygous variants (SLC41A3, CLIP, ZFYVE20)
Only the homozygous missense variation (g. 15,116,371
G >A) in ZFYVE20, resulting in a glycine to arginine sub-
stitution at position 425 (p.Gly425Arg), segregated with
disease in the family as confirmed by Sanger sequencing
(Figure 2).
Cellular endocytosis and recycling analysis
The uptake and recycling rates of transferrin (Tf ) in pa-
tient (PA) and age and passage matched control (CB) fi-
broblasts were studied using described methods [5,13].
In brief, cells were imaged by total internal reflection
fluoresce microscopy (TIRF) at 1 frame/sec continu-
ously for 20 minutes, during which Alexa-488-Tf was
added to the medium, maintained for 10 minutes and
then removed. Raw TIRF images obtained over time
from control (Figure 3A) or patient (Figure 3B) single cells,
together with mean and SEM from three independent cells
are illustrated in Figure 3C. Data normalized to the max-
imal uptake recorded in each cell is shown (Figure 3D).
Tf associated rapidly and saturably with both PA and
CB cells, displaying kinetic constants consistent with
binding to the transferrin receptor [13-16], and similar
to those previously determined in other mammalian cell
types. However, in PA cells Tf saturated at a lower max-
imal rate (Figure 3C), and displayed a significantly faster
rate of recycling compared to CB cells (Figure 3C,D,G).
The accumulation of Tf in the three dimensional volume of
the cell was visualized immediately before the removal of
extracellular Tf, by collecting 10 image stacks using struc-
tured light illumination. Accumulation of Tf in PA cells
was only 50% of that observed in CB cells (Figure 3E,F).
Results demonstrate a defect in the early endocytic pathway
with enhanced recycling rate and decreased steady-state
accumulation of ligand in cells harboring the p.G425R
mutation.
Western blotting did not show significant differences
between PA and CB total cellular levels of Rbsn-5 and
other key proteins within the early endocytic pathway
(Figure 4A), ruling out the possibility that the p.G425R
mutation might result in loss of protein stability and en-
hanced degradation. Moreover, no consistent difference
in the total level of the transferrin receptor (TfR) was
noted, suggesting that the alterations in Tf endocytosis
in PA cells are not simply a consequence of lower
Figure 2 Pedigree of affected case. Circles represent females, square represents male, black symbol represent affected case.
Stockler et al. Orphanet Journal of Rare Diseases 2014, 9:141 Page 5 of 11
http://www.ojrd.com/content/9/1/141
receptor levels. Immunofluorescence staining with anti-
bodies to Rbsn-5, EEA1, clathrin and TfR showed similar
distribution in CB and PA cells and comparable to that
previously described for Cos-1 cells (Figure 4B).
Finally, we investigated restoration of function trans-
fecting PA and BC cells by electroporation with either a
control plasmid encoding soluble RFP or RFP-Rbsn-5.
After 48 h, cells were exposed to Alexa488-Tf for the
indicated time (Figure 5) and accumulation per cell was
measured. CB fibroblasts expressing RFP (Figure 5A,C)
or RFP-Rbsn-5 (Figure 5B,D) accumulated a similar amount
of Tf over different time points analyzed (Figure 5C,D and I).
In contrast, Tf uptake into PA cells was lower than that
seen in CB cells, and significantly increased upon expression
Figure 3 Dynamics of transferrin association and dissociation from human fibroblasts. TIRF images of the entire cell from control (A) or
affected (B) individual at 300 seconds following addition of fluorescent transferrin. Red rectangles represent region depicted in the time series
shown to the right. Transferrin was removed from the medium at t = 600. C. Quantification of the amount of transferrin in the TIRF image of the
entire cell, plotted as the mean and SEM of each time point from three individual cells. D. The mean from the data in C was recalculated as a
percent of maximal signal. Structured light epifluorescence image stacks from control (E) or affected (F) individual taken at t = 600, projected into
a single plane. G. Quantification of signal in the structured light images from 3 individual cells. Statistical significance was calculated by 2-tailed
Student t-test. Similar experiments were conducted with three independent passages, with similar results.
Figure 4 Western blotting and subcellular distribution of endocytic pathway proteins. A. Western blotting: Cells from control (CB) or
affected (PA) individual were grown to 80% confluence, and whole cell lysates obtained. Serial dilutions of equal total protein concentrations of
the cell extracts were processed to enable quantification, as indicated. B. Subcellular distribution: Cells from control (CB) or affected (PA)
individual were grown on glass coverslips, fixed, permeabilized and stained with antibodies to the proteins indicated above each panel. Shown in
black and white are structured light epifluorescence image stacks from representative cells, projected into a single plane.
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of RFP-Rbsn-5 (Figure 5G,H and I). Experiments suggest
that the observed defect in transferrin trafficking is attrib-
utable to the Rbsn-5 G425R mutation.
We then tested whether the effect of the Rbsn-5 p.
G425R mutation might be restricted to Tf recycling kin-
etics, or as expected, would affect the activities of other
receptors. Depletion of Rbsn-5 causes altered subcellular
distribution of mannose-6-phosphate receptors affecting
the biosynthetic transport of cathepsin D from Golgi to
the lysosomal lumen [17]. Consistent with this function,
we found a reduction of cathepsin D activity to 35% of
the one measured in control fibroblasts (404 ± 53 versus
1158 ± 178 nmol/h × mg, n = 3). In Western blotting, the
intensity of precursor cathepsin D was slightly higher in
the patient fibroblast, in contrast the intensity of 33 kDa
heavy chain of the mature cathepsin D was diminished to
42% of the control (Figure 6A), indicating compromised
cathepsin D processing to mature, proteolytic active ca-
thepsin D. Targeted WES analysis of CTSD (with ≥25X
coverage of all exons) did not identify any rare, damaging
variants.
To further assess the consequences of impaired traffick-
ing, growth rates and subcellular morphology of the PA
cells were analyzed. A slower proliferation rate was found
(Figure 6B), as well as the presence of translucent vacuoles
in the perinuclear region (Figure 6C). These vacuoles were
negative for Tf even after prolonged uptake, and negative
for lysotracker staining (not shown). The presence of
vacuoles was not mitigated by transient expression of
Rbsn-5, and thus may be the result of persistent changes
caused by endocytic pathway abnormalities, which are not
reversible in a short-term experiment. Electron micro-
graphs of the patient’s fibroblasts (Figure 6D-F) showed
an excess of intermediate filaments in either a perinuclear
band, associated with the plasmalemma, or throughout
the cytoplasm, as well as lysosomes containing small gran-
ules of electron opaque material. Cytoplasmic organelles
were sparse when compared to fibroblasts derived from
normal individuals.
Discussion
Here we report a complex clinical phenotype associated
with a mutation in exon 14 of ZFYVE20, leading to muta-
tion of glycine 425 to arginine in Rbsn-5, which appears to
affect the dynamics of receptor trafficking in the endocytic
pathway. To our knowledge this is the first report of mu-
tations in this highly conserved multidomain protein, and
the complex ensuing clinical phenotype is consistent with
the fundamental role of endocytosis and recycling in
mammalian cell function, and with the critical role that
Rbsn-5 plays in this multistep process.
The location of this mutation is in the central residue
in an NG(D/E) motif that stands out as an island of con-
servation within an otherwise variable segment in higher
metazoans (mammals, birds, fish, reptiles) (Figure 7).
We are currently investigating the effect of this mutation
Figure 5 Rescue of Tf accumulation by wild-type Rbsn-5. Cells from CB (A-D) or PA (E-H) were transfected with plasmids encoding RFP (A,C,E,G)
or RFP-Rbsn5 (B,D,F,H). After 48 h, cells were exposed to Alexa-488-Transferrin for 5–30 min, washed briefly and fixed. Representative images of RFP
(A,E) or RFP-Rbsn5 (B,F) and corresponding Tf images (C,G and D,H). Light intensity of Tf signal per cell was quantified (I). Plotted are means and SEM
of 50–100 cells from 4 independent experiments. Statistical significance was calculated using 2-tailed paired Student t-test, where the means of each
time point are paired as indicated.
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on the tertiary structure of the protein using X-ray crys-
tallography and small angle X-ray scattering. Mutation
to arginine as found in this patient, represents a major,
non-conservative change that could result in loss of func-
tion with respect to flexibility, structural organization,
and/or intermolecular interactions, in addition to poten-
tial effects on membrane targeting, stability, solubility, or
oligomeric state. These alterations are likely to affect the
function of Rbsn-5 to generally control receptor traf-
ficking, which in turn would affect the levels and activity
of multiple receptor species in multiple cell types, thus
underlying multi-organ level abnormalities. Consistent
with this possibility, we find evidence for enhanced re-
ceptor recycling when directly visualizing Tf endocyto-
sis, as well as reduced residual cathepsin D activity with
predominance of pre-cathepsin D protein, indicating
Figure 6 Additional findings in fibroblasts A. Western blot of extracts from cells from control (CB) or affected (PA) individual with goat anti-human
CatD antibody, indicating 53-kDa proenzyme precursor (preCatD) and the processed 33 kDa heavy chain (CatD) of cathepsin-D. Detection of β-actin
demonstrated similar amounts of protein loading for patient and control lysates. B. Cumulative cell numbers calculated at each passage over a 30 day
period. C. Phase images of CB (left) and PA (right) fibrobasts. Arrows indicate translucent vacuoles present in many of the PA cells. Electron micrographs of
normal (D) and patient (E) fibroblasts. F. Nucleus (N) from patient’s fibroblast surrounded by a dense band of filamentous material.
Figure 7 Position of G425R mutation in the context of full-length Rbsn-5. A. Diagram of Rabenosyn-5 with functional domains indicated.
Red asterisk indicates position of mutation. B. Amino acid conservation among species in the region of the mutation.
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impaired trafficking of this enzyme in the endolysoso-
mal system. These phenotypes have been previously
associated with decreased levels of Rbsn-5 achieved
through siRNA silencing [5,17]. Understanding how the
G425R mutation phenocopies Rbsn-5 depletion will re-
quire further structure-function studies outside the scope
of the present findings.
The mechanisms by which deficiency of Rbsn-5 at the
cellular level lead to the complex features of this patient
are suggested by cases in which specific defects in the
endosomal/lysosomal pathway produce complex clinical
phenotypes. For example, primary cathepsin D deficiency
[12,18], causes early onset epileptic encephalopathy and
microcephaly, features, which are prominent in our pa-
tient’s clinical phenotype. Similarly, mucolipidosis type
III, a lysosomal trafficking disorder caused by loss of
mannose-6-phosphate targeting signals on lysosomal
proteins, results in dysmorphic facial features, small
stature and dysostotic bone changes similar to those ob-
served in our patient [19,20]. The electron-dense material
contained in the lysosomes of this patient’s fibroblasts
may indicate lysosomal storage due to reduced intralyso-
somal amounts of enzymes dependent on mannose-6-
phosphate mediated trafficking [19,20].
Alterations in endocytic trafficking caused by Rbsn-5
deficiency might be the common denominator for the
pleiotropic clinical manifestations observed in this pa-
tient. For example, the severe dyslipidemia developed in
response to ketogenic diet may in part be attributable to
impaired LDL receptor trafficking. While the child’s initial
vitamin B12 deficiency might in part be of nutritional ori-
gin, in combination with the observed albuminuria, im-
paired endocytic trafficking in proximal renal tubular
cells, where transcobalamin and albumin are reabsorbed
by the Megalin/cubilin receptor protein [21], might have
been an aggravating factor. Likewise, the urine methylma-
lonic acid excretion and the red blood cell macrocytosis,
despite cobalamin supplementation, may be due to de-
fective intracellular trafficking of cobalamin. Although
not entirely explained, the disproportionate synthesis
of methylcobalmin and adenosylcobalamin in the pa-
tient’s fibroblasts might be an indication of this pro-
posed mechanism as well.
There is also a possible relation between the observed
bone marrow changes and Rbsn-5 deficiency. Missense
mutations leading to depletion of Vps45, a known Rbsn-
5 binding partner, have recently been reported in pa-
tients with severe neutropenia, bone marrow fibrosis
and early lethality [22,23]. The reticular fibrosis found in
our patient’s bone marrow resembles these findings.
Functional folate deficiency caused by folate antagonistic
anti-epileptic drugs (e.g. lamotrigine) and the KD also
could explain these findings, although hematological
studies proving such side effects are lacking.
The cumulative effects of Rbsn-5 deficiency on cellular
function are manifested by a slow growth rate of the pa-
tients fibroblasts, compared to age matched controls, as
well as by morphological abnormalities such as the accu-
mulation of translucent vacuoles and intermediate fila-
ments. The extent to which these abnormalities are
directly attributable to Rbsn-5 function, or are secondary
to chronic impairment of endocytic trafficking is unclear,
but the failure of Rbsn-5 wild-type transfection to revert
vacuolar phenotype is suggestive of the latter possibility.
Nevertheless, impaired cytoskeletal dynamics have been
seen in models of Rbsn-5 deficiency [24], and could ex-
plain the accumulation of intermediate filaments in the
perinuclear cytoplasm of our patient. While changes in
neurotransmitter recycling [25-27], cytoskeletal dynam-
ics [28], or dendritic branching [29] are possible causes,
the precise mechanism by which this mutation contrib-
utes to the pathogenesis of epilepsy, a key feature in this
patient, remains to be determined.
Conclusions
Overall, based on the critical role of Rbsn-5 in endocytic
pathways, mutations affecting its functions are likely the
basis of multi systemic disorders such those presented
here. More patients with Rbsn-5 deficiency need to be
identified in order to delineate the specific clinical and
biochemical phenotype of this gene defect. Patients with
epilepsy, growth retardation, dysmorphic features, multi-
system involvement (bone abnormalities, myelodyplasia,
albuminuria) and unexplained biochemical findings such
as cobalamin deficiency and partial cathepsin D deficiency
should be considered at risk.
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